Suven Life Sciences shares declined 5.67% to a low of ₹308.05 on Thursday following the company's quarterly results announcement. According to reports from Essential Business Intelligence, the stock traded 4.44% lower at ₹312.05 as of 1:34 p.m. on the NSE, significantly underperforming the benchmark Nifty index which showed marginal gains during the same period.
The company reported a consolidated net loss of ₹127.61 crore for the first quarter of FY27, representing a significant deterioration from the loss of ₹51.52 crore recorded in the same quarter of the previous year. As reported by Business Standard, revenue showed exceptional growth, increasing 90.91% to ₹3.57 crore from ₹1.87 crore in Q1 FY26, indicating substantial operational activity. The latest quarterly results show continued challenges with net loss of ₹45.60 crore in Q3 FY26, though this represents an improvement from the ₹101.92 crore loss recorded in Q2 FY26.
For the full financial year 2025, Suven Life Sciences reported a net loss of ₹276.34 crore compared to ₹160.75 crore in the previous year, indicating significant year-over-year deterioration. However, revenue showed positive growth with sales rising 6.76% to ₹7.11 crore in FY26 from ₹6.66 crore in FY25. The company's operational metrics show operating margin of -33.39% for FY26, reflecting ongoing challenges in achieving profitability despite revenue growth.
Despite the recent decline, Suven Life Sciences shares have demonstrated strong performance over longer timeframes, rising 86.86% year-to-date and 28% in the last 12 months, according to Essential Business Intelligence data. The current decline represents a significant reversal from this positive trend, with the stock underperforming the broader market indices during Thursday's trading session. The company has scheduled its 37th Annual General Meeting on August 25, 2026, indicating continued corporate governance activities despite financial challenges.
